AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12496059
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum (part of nicotine replacement therapy)
Trial: 6444379
Drug: 20 percent
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 percent benzoyl peroxide lotion
Trial: 28947449
Drug: Lifestyle Matters
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle Matters intervention (4-month occupational therapy intervention)
Trial: 25824586
Drug: Valacyclovir (vACV)
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valacyclovir (vACV) 8 g/day
Trial: 25824586
Drug: Valganciclovir (vGCV)
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Valganciclovir (vGCV) 900 mg/day
Trial: 23429202
Drug: Avatar therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avatar therapy
Trial: 23429202
Drug: Crossover control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover control (TAU vs Avatar therapy)
Trial: 17220051
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (rosiglitazone 8 mg)
Trial: 17220051
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (rosiglitazone 8 mg)
Trial: 12644428
Drug: L-bupivacaine 0.75%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-bupivacaine 0.75% and lidocaine 2%
Trial: 8529086
Drug: Behavioral and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral and educational cardiac rehabilitation program, including 6 weekly group sessions and personalized behavior modification program.
Trial: 7008293
Drug: Standard antirejection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antirejection treatment (SAT)
Trial: 31773201
Drug: ISB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISB with DEX (1 ml DEX + 8 ml 0.75% ropivacaine)
Trial: 31773201
Drug: ISB alone
RxNorm normalized name: ISB 1342
DrugBank: ISB 1342 (DB17251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISB alone (1 ml normal saline + 8 ml ropivacaine)
Trial: 31663769
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogen (o‐CEE; n = 109)
Trial: 31663769
Drug: Transdermal 17β‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17β‐estradiol (t‐E2; n = 107)
Trial: 26600287
Drug: Topical overnight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical overnight application of lidocaine for 10 weeks
Trial: 26600287
Drug: Topical overnight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical overnight application of lidocaine
Trial: 11976562
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g young barley leaf extract (BL)
Trial: 11976562
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg vitamin C and 200 mg vitamin E (CE)
Trial: 11276473
Drug: Optimum medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimum medical management (risk factor reduction and initiation of antiplatelet therapy)
Trial: 29405226
Drug: Solanezumab (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solanezumab (400 mg) every 4 weeks for 80 weeks
Trial: 29405226
Drug: Solanezumab (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solanezumab (400 mg)
Trial: 28370397
Drug: Comprehensive education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive education about dental implants delivered before the interview
Trial: 28370397
Drug: Comprehensive education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive education about dental implants delivered after completing the questionnaire
Trial: 28370397
Drug: Information about
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information about implants from relatives or own dentist
Trial: 28370397
Drug: Information about
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information about implants from the study dentist
Trial: 21250860
Drug: Alcaftadine 0.25%
RxNorm normalized name: ALCAFTADINE 0.25% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcaftadine 0.25% ophthalmic solution
Trial: 19994698
Drug: Wooden needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wooden needle treatment
Trial: 19994698
Drug: Alprazolam (western
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (western medicine)
Trial: 7487127
Drug: Granisetron (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (3 mg/day)
Trial: 7654434
Drug: Ondansetron (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (24 mg/day)
Trial: 7654434
Drug: Granisetron (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (3 mg/day) in patients receiving cisplatin
Trial: 7654434
Drug: Ondansetron (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (24 mg/day) in patients receiving cisplatin
Trial: 7654434
Drug: Granisetron (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (3 mg/day) in patients receiving ifosfamide
Trial: 7654434
Drug: Ondansetron (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (24 mg/day) in patients receiving ifosfamide
Trial: 31039656
Drug: Metformin sterosomes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin sterosomes
Trial: 31039656
Drug: Metformin-free solution
RxNorm normalized name: metformin Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin-free solution aerosol
Trial: 31039656
Drug: Metformin sterosomes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin sterosomes and metformin-free solution aerosol
Trial: 27465727
Drug: Enzyme-Treated Asparagus
RxNorm normalized name: Asparagus
DrugBank: Asparagus (DB10503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme-Treated Asparagus Extract (ETAS) 150 mg/d for 28 days
Trial: 22510424
Drug: Lixivaptan 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixivaptan 100 mg once daily
Trial: 21037433
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (oxaliplatin- or irinotecan-based, at least 3 cycles)
Trial: 17960520
Drug: Intrahospital supervised
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrahospital supervised exercise training (3 weekly sessions of resistance and aerobic training for 8 weeks)
Trial: 10584996
Drug: Nadroparin administered
RxNorm normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin administered by the venous line
Trial: 10584996
Drug: Nadroparin administered
RxNorm normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin administered by the arterial line
Trial: 10584996
Drug: Nadroparin with
RxNorm normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin with part of the dose added to the priming solution
Trial: 10584996
Drug: Nadroparin administration
RxNorm normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin administration (both routes)
Trial: 8712133
Drug: Baseline fibrinogen
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline fibrinogen concentration > or = 300 mg/dl
Trial: 6354929
Drug: Captopril 12.5
RxNorm normalized name: captopril 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 12.5 mg t.i.d.
Trial: 6354929
Drug: Captopril 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 37.5 mg b.i.d.
Trial: 6354929
Drug: Captopril plus
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril plus Hydrochlorothiazide (C plus H) 12.5 mg
Trial: 6354929
Drug: Captopril plus
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril plus Hydrochlorothiazide (C plus H) 25 mg
Trial: 6354929
Drug: Captopril plus
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril plus Hydrochlorothiazide (C plus H) 37.5 mg
Trial: 6354929
Drug: Captopril plus
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril plus Hydrochlorothiazide (C plus H) 50 mg
Trial: 30683103
Drug: Vaginal gel
RxNorm normalized name: VAGINAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal gel and oral tablets for HIV prevention
Trial: 27734104
Drug: hyperinsulinaemic hypoglycaemia
RxNorm normalized name: Drugs for treatment of hypoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyperinsulinaemic hypoglycaemia (HH; i.v. bolus of 0.1 U/kg insulin)
Trial: 27734104
Drug: hyperinsulinaemic euglycaemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyperinsulinaemic euglycaemia (HE; i.v. bolus of 0.1 U/kg insulin and 20% glucose)
Trial: 15227557
Drug: Sequential Multi
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Multi Layered Perceptron (SMLP)
Trial: 7949205
Drug: Aminoglutethimide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide (500 mg daily)
Trial: 7949205
Drug: Aminoglutethimide (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide (lower dose without hydrocortisone)
Trial: 7949205
Drug: Aminoglutethimide (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide (lower dose)
Trial: 7949205
Drug: Aminoglutethimide (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide (initial high dose)
Trial: 17010995
Drug: FEWP monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEWP monotherapy (36 g/day, n=86)
Trial: 15095554
Drug: TPA (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPA (standard 0.9 mg/kg TPA therapy)
Trial: 7640924
Drug: iomeprol 350
RxNorm normalized name: Iomeprol 350 MG/1 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iomeprol 350 mg I ml‐1
Trial: 7640924
Drug: iohexol 350
RxNorm normalized name: iohexol 350 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol 350 mg I ml‐1
Trial: 7640924
Drug: iopamidol 370
RxNorm normalized name: iopamidol 370 mg iodine/mL (76 %) INTRAVEN KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopamidol 370 mg I ml‐1
Trial: 2520297
Drug: Daily vitamin‐mineral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vitamin‐mineral supplement containing 2 or 3 mg of vitamin B6 for 9 days before surgery and multivitamin supplement containing 0.4, 0.8 or 2 mg of vitamin B6 for 3 months postoperatively
Trial: 2520297
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of supplemental vitamin B6 per day during the fourth month
Trial: 31246878
Drug: BWL therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BWL therapy (30-minute exposure to waking white light enriched with blue for 4 weeks)
Trial: 31246878
Drug: N-BWL (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-BWL (no light therapy)
Trial: 23958818
Drug: Intravenous hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydromorphone
Trial: 14699198
Drug: Multiple-family group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-family group treatment
Trial: 2173435
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg once daily (4000 anti Xa U)
Trial: 2173435
Drug: Unfractionated calcic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfractionated calcic Heparin (5000 U.I. every eight hours)
Trial: 73013
Drug: Mixture of
RxNorm normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture of A.M.L. cells and B.C.G. given on 4 occasions early in remission
Trial: 73013
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with killed allogeneic A.M.L. cells and Glaxo B.C.G. (Control group)
Trial: 28225297
Drug: Simethicone (co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone (co-administered with CIN)
Trial: 21723989
Drug: 4-implant bar
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-implant bar attachment
Trial: 21723989
Drug: 2-implant bar
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-implant bar attachment
Trial: 21723989
Drug: Criterion-based retention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Criterion-based retention scores for all treatments
Trial: 21723989
Drug: O-ring treatment
RxNorm normalized name: Padimate O
DrugBank: Padimate O (DB11570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: O-ring treatment
Trial: 21723989
Drug: 4-implant bar
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-implant bar treatment
Trial: 19403468
Drug: Zolpidem at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem at 0.25 mg/kg per day (maximum of 10 mg/day)
Trial: 12765594
Drug: Bemiparin (heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bemiparin (heparin of low molecular weight), injected subcutaneously at 3500 IU/day for the first 10 days and 2500 IU/day up to 90 days
Trial: 8951932
Drug: Bosentan 250
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan 250 mg i.v.
Trial: 1955637
Drug: SMX168-poly-L-tyrosine skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMX168-poly-L-tyrosine skin test reagent
Trial: 7048919
Drug: 5 percent
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Lidocaine 5 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 percent topical acyclovir ointment
Trial: 25551475
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality (VR) treatment
Trial: 23850491
Drug: Sitimagene ceradenovec
RxNorm normalized name: Sitimagene ceradenovec
DrugBank: Sitimagene ceradenovec (DB04907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitimagene ceradenovec (1×10^12 viral particles) followed by ganciclovir (5 mg/kg intravenously twice a day) in addition to standard care
Trial: 16415304
Drug: CEE/MPA (0.625/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE/MPA (0.625/2.5 mg daily)
Trial: 12571649
Drug: Advice to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advice to eat two portions of oily fish each week or take three fish oil capsules daily
Trial: 9199864
Drug: Electrical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical stimulation (ES) treatment for two weeks
Trial: 3978008
Drug: 0.0625% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0625% bupivacaine 6.25 mg h‐1 infusion
Trial: 3978008
Drug: 0.125% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% bupivacaine 10 ml h‐1 infusion
Trial: 3978008
Drug: 0.125% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% bupivacaine 12.5 mg h‐1 infusion
Trial: 3978008
Drug: 0.125% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% bupivacaine 18.75 mg h‐1 infusion
Trial: 22388476
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (medication or cognitive-behavioral therapy)
Trial: 22388476
Drug: Remission of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remission of mothers' depression (regardless of treatment assignment)
Trial: 18755319
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg calcium carbonate plus 400 IU vitamin D(3) per day
Trial: 8743187
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation for 6 months
Trial: 6356756
Drug: Diazepam (0.17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.17 mg/kg)
Trial: 29595123
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination formulation (salbutamol 4 mg and ambroxol 15 mg)
Trial: 29595123
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of salbutamol 4 mg and ambroxol 15 mg
Trial: 29595123
Drug: Ambroxol 15
RxNorm normalized name: ambroxol 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol 15 mg
Trial: 27919965
Drug: Bevacizumab combined
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab combined with docetaxel (10 mg/kg bevacizumab i.v. plus 50 mg/m2 docetaxel i.v.)
Trial: 27919965
Drug: Bevacizumab combined
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab combined with paclitaxel (10 mg/kg bevacizumab i.v. plus 90 mg/m2 paclitaxel i.v.)
Trial: 27919965
Drug: Bevacizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (15 mg/kg i.v.) alone after progression
Trial: 24838177
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg once daily for 5 days (Period 1)
Trial: 24838177
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg once daily coadministered with telaprevir 750 mg every 8 h for 10 days (Period 2)
Trial: 19996954
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml of bupivacaine mixed with contrast
Trial: 19996954
Drug: 0.25 ml
RxNorm normalized name: mineral oil 0.25 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 ml of bupivacaine mixed with contrast
Trial: 17511185
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg sufentanil and 2.5 mg bupivacaine
Trial: 17511185
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg tramadol and 2.5 mg bupivacaine
Trial: 15895421
Drug: Repetitive transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive transcranial magnetic stimulation (rTMS, 15 Hz, 110% above motor threshold, 10 daily sessions)
Trial: 1355797
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg zinc daily
Trial: 30025953
Drug: Current treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current treatment with NSAIDs and biologics
Trial: 26989846
Drug: Telmisartan/Amlodipine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan/Amlodipine combination tablets (bedtime administration)
Trial: 26989846
Drug: Telmisartan/Amlodipine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan/Amlodipine combination tablets (morning administration)
Trial: 26989846
Drug: Telmisartan/Amlodipine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan/Amlodipine combination tablets (both timings)
Trial: 12073203
Drug: Heparin-coated circuits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuits with reduced systemic heparinization
Trial: 12073203
Drug: Heparin-coated circuits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuits with full systemic heparinization
Trial: 8011007
Drug: Standard formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formulation (Primperan)
Trial: 2679289
Drug: Antiplatelet or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet or anticoagulant therapy, early initiation
Trial: 766619
Drug: 0.25 g
RxNorm normalized name: AMICAR 0.25 GM/mL Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 g hydrocortisone hemisuccinate
Trial: 766619
Drug: 0.50 g
RxNorm normalized name: SALICYLIC ACID 0.50 g in 100 g TOPICAL SOAP [ORIPAN GOLD 100g]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 g hydrocortisone hemisuccinate
Trial: 766619
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g hydrocortisone hemisuccinate
Trial: 7312235
Drug: Conventional paracervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional paracervical block (almost simultaneous injection of the 2 sides)
Trial: 7312235
Drug: Paracervical block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracervical block with a 10-minute interval between injections
Trial: 29794277
Drug: IV ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketamine (LDK) 1 mg/kg